Role of modeling and simulation in pediatric investigation plans.
about
Developmental pharmacokinetics in pediatric populationsPharmacogenetics-based warfarin dosing in childrenNeonatal drug therapy: The first frontier of therapeutics for childrenPhysiologically Based Pharmacokinetic Predictions of Tramadol Exposure Throughout Pediatric Life: an Analysis of the Different Clearance Contributors with Emphasis on CYP2D6 Maturation.Integration of PKPD relationships into benefit-risk analysisFirst dose in neonates: are juvenile mice, adults and in vitro-in silico data predictive of neonatal pharmacokinetics of fluconazole.Predicting neonatal pharmacokinetics from prior data using population pharmacokinetic modeling.Extrapolation of efficacy and other data to support the development of new medicines for children: A systematic review of methods.Formalizing an integrative, multidisciplinary cancer therapy discovery workflowCharacterizing variability in warfarin dose requirements in children using modelling and simulation.Population pharmacokinetics of deferiprone in healthy subjects.Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and ChildrenPharmacokinetics of tralokinumab in adolescents with asthma: implications for future dosing.Role of modelling and simulation: a European regulatory perspective.Physiologically based pharmacokinetic (PBPK) modeling in children.Dosage individualization in children: integration of pharmacometrics in clinical practice.Neonatal medicines research: challenges and opportunities.Toward Optimum Benefit-Risk and Reduced Access Lag For Cancer Drugs in Asia: A Global Development Framework Guided by Clinical Pharmacology Principles.Population Pharmacokinetic and Exposure-Response Analyses of Prasugrel in Pediatric Patients with Sickle Cell Anemia.Population pharmacokinetics and dosing recommendations for the use of deferiprone in children younger than 6 years.Have physiologically-based pharmacokinetic models delivered?A neonatal amikacin covariate model can be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates.Physiologically based pharmacokinetic models in the prediction of oral drug exposure over the entire pediatric age range-sotalol as a model drug.The influence of the European paediatric regulation on marketing authorisation of orphan drugs for childrenThe risks of methodology aversion in drug regulation.The effect of organic solvents on enzyme kinetic parameters of human CYP3A4 and CYP1A2 in vitro.Pharmacometrics for regulatory decision making: status and perspective.Evaluation of a System-specific Function to Describe the Pharmacokinetics of Benzylpenicillin in Term Neonates Undergoing Moderate Hypothermia.A predictive pharmacokinetic/pharmacodynamic model of fentanyl for analgesia/sedation in neonates based on a semi-physiologic approach.Representation of older patients in clinical trials for drug approval in Japan.Developmental pharmacology; filling one knowledge gap in pediatric anesthesiology.Adaptive paediatric investigation plans, a small step to improve regulatory decision making in drug development for children?
P2860
Q27002933-2DCFABA5-57F7-41D2-B326-9D9B80D14ABFQ27008320-8DFC9D12-986A-4B2A-AB59-8298D24CC2EBQ27013749-80760C95-8D72-43A7-A07F-7683941260C8Q27312881-8500D463-44ED-472B-8326-66D6FACB903CQ30671571-CA1328B1-6BB3-42C0-9FDD-38202873CCFFQ30844731-B9A3D232-631A-4BF3-877B-9B7765994CB2Q30938796-73A4B361-BDC3-43FC-9A47-A82E62BED107Q31060832-451FB6E0-8A71-4ABB-B2C2-021F0DB47DAFQ33693626-2F921C2C-B82F-446F-8DDC-C01847322C07Q34209582-7E8891BA-9EB6-4A58-A626-804E66B2F3E2Q34635568-C054332E-9915-4929-B366-27DFB4EC895FQ36322918-5F135013-5D56-4BAE-B193-35D70472ED74Q36410129-CB68B918-74CA-4CBF-AE02-253AED63786EQ37976876-ADEC0D89-4268-45F6-8EDF-9616DA6C6985Q38016332-4D6015D6-5A9B-46C5-905E-7CF8FD691236Q38240055-871231EE-F369-406A-B092-6323F5C14C12Q38469763-9E243A95-0719-4C41-AD6D-683B9ACAE201Q38719689-0EF75FD4-ED17-464A-86B3-BFC86F94C707Q38746324-31B89C15-BAA3-4401-88FC-852F25386C5BQ39377048-75BF5B77-C105-455D-A5B3-B648A143EA28Q39728369-AE623441-C9D7-49E5-969B-87DE19065A61Q41477321-573C70A7-CD20-45A9-8DD2-E82F678897DEQ41975490-5C907197-063C-4626-915E-F046BE3A506AQ42860137-D99787B5-CC6B-469A-B178-3BF970374C4BQ43762097-123414BC-5049-40D1-8C45-FF619CE9F875Q44716047-3DE42163-0A17-44DF-9B4B-4DBE134AC108Q46966642-8969E88D-2661-4C93-850C-835E2D8B1BBAQ47833944-B9F8EE41-430E-4202-B66F-C3F71EB7C34EQ48010349-741CE1BE-F11D-4D70-BEA8-D3403C4B718AQ48282413-D2A60C4F-63C5-403B-B466-B05C070BDDC3Q48286613-C8A4A4FE-098E-44AC-B199-8D3BFAB2DF45Q50499560-C5A492DE-DCA7-4ED5-8B6C-066ABEAAAF37
P2860
Role of modeling and simulation in pediatric investigation plans.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Role of modeling and simulation in pediatric investigation plans.
@en
Role of modeling and simulation in pediatric investigation plans.
@nl
type
label
Role of modeling and simulation in pediatric investigation plans.
@en
Role of modeling and simulation in pediatric investigation plans.
@nl
prefLabel
Role of modeling and simulation in pediatric investigation plans.
@en
Role of modeling and simulation in pediatric investigation plans.
@nl
P2093
P2860
P50
P1476
Role of modeling and simulation in pediatric investigation plans.
@en
P2093
Agnes Saint Raymond
Efthymios Manolis
Spiros Vamvakas
Tariq Eldirdiry Osman
P2860
P304
P356
10.1111/J.1460-9592.2011.03523.X
P577
2011-01-18T00:00:00Z